Pharmacotherapy of obsessive-compulsive disorder: Experience with the selective serotonin reuptake inhibitors

B. Vythilingum, C. Cartwright, E. Hollander

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

Since the introduction of the selective serotonin reuptake inhibitors (SSRIs) a decade ago, they have become first-line agents in the treatment of obsessive-compulsive disorder (OCD). Numerous clinical trials have confirmed their efficacy, and established their superior risk-benefit ratio in comparison with clomipramine, a non-selective serotonin reuptake inhibitor. Relatively higher doses and longer duration of treatment may be necessary to effect a response in OCD, with long-term treatment being required to maintain therapeutic gains. Despite the advances represented by the SSRIs, treatment resistance remains a problem. While no one solution exists, various strategies, including pharmacotherapy augmentation, look promising. (C) 2000 Lippincott Williams and Wilkins.

Original languageEnglish (US)
Pages (from-to)S7-S13
JournalInternational Clinical Psychopharmacology
Volume15
Issue numberSUPPL. 2
DOIs
StatePublished - Jan 1 2000
Externally publishedYes

Keywords

  • Obsessive-compulsive disorder
  • Pharmacotherapy
  • SRIs
  • SSRIs
  • Serotonin

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Pharmacotherapy of obsessive-compulsive disorder: Experience with the selective serotonin reuptake inhibitors'. Together they form a unique fingerprint.

  • Cite this